Thu, Aug 21, 2014, 6:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

  • valentinfernandezgarcia valentinfernandezgarcia Apr 16, 2010 5:04 AM Flag

    Rintatolimod (Ampligen) update

    4/08/2010 Hemispherx Biopharma completes phase II trials in HIV infections. (source FDA).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ... do you have a link?

      Thanx!

      Best wishes!

      • 1 Reply to steelman068
      • Rintatolimod - (Update)Pipeline Drug Development History Event Date Development history
        4/8/2010 Hemispherx Biopharma completes phase II trials in HIV infections
        2/8/2010 Discontinued - Preclinical for Smallpox in USA (IV)
        12/1/2009 Hemispherx Biopharma receives complete response letter from the US FDA for rintatolimod in Chronic fatigue syndrome
        10/22/2009 Pharmacodynamics data from a preclinical study in macaque monkeys in Influenza virus infections released by Hemispherx Biopharma
        5/26/2009 The US FDA advises Hemispherx Biopharma of a possible brief delay in its action report for the NDA filing of rintatolimod for Chronic fatigue syndrome
        2/18/2009 The US FDA extends the PDUFA review date for the NDA filing of rintatolimod for Chronic fatigue syndrome
        11/18/2008 Hemispherx Biopharma enters into a research contract agreement with Lovelace Respiratory Research Institute to conduct additional preclinical studies with rintatolimod for Chronic fatigue syndrome in USA
        7/8/2008 The US FDA accepts Hemispherx Biopharma's NDA filing of rintatolimod for review in Chronic fatigue syndrome

 
HEB
0.270.00(+1.50%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.